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One of the most dynamic and fruitful areas of current health-related research concerns the 
various roles of the human microbiome in disease. Evidence is accumulating that interactions 
between substances in the environment and the microbiome can affect risks of disease, in 
both beneficial and adverse ways. Although most of the research has concerned the roles of 
diet and certain pharmaceutical agents, there is increasing interest in the possible roles of 
environmental chemicals. Chemical risk assessment has, to date, not included consideration 
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the microbiome could lead to significant error in risk assessment results. Our purpose in this 
commentary is to summarize some of the evidence supporting our hypothesis and to urge the 
risk assessment community to begin considering and influencing how results from 
microbiome-related research could be incorporated into chemical risk assessments. 
An additional emphasis in our commentary concerns the distinct possibility that research 
on chemical-microbiome interactions will also reduce some of the significant uncertainties 
that accompany current risk assessments. Of particular interest is evidence suggesting that the 
microbiome has an influence on variability in disease risk across populations and (of 
particular interest to chemical risk) in animal and human responses to chemical exposure. The 
possible explanatory power of the microbiome regarding sources of variability could reduce 
what might be the most significant source of uncertainty in chemical risk assessment. 
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In 2017 the National Academies of Sciences, Engineering, and Medicine convened a 
committee to review the available research literature on interactions between the human 
microbiome and environmental chemicals and to make recommendations for research that is 





This article is protected by copyright. All rights reserved. 
 
The work of the committee was sponsored by the Environmental Protection Agency and 
the National Institute of Environmental Health Sciences and was published in 2018 
(NASEM, 2018). The National Academies report (Environmental Chemicals, the Human 
Microbiome, and Health Risk: A Research Strategy) does not concern the well-established 
domain of microbial risk assessment but is entirely focused on the types of interactions that 
can occur between environmental chemicals and the human microbiome, the possible 
consequences for health of these interactions, and the challenges that arise in considering 
such interactions in chemical risk assessments. The committee was careful to emphasize that 
a structured research effort must be undertaken to understand whether such interactions have 
important health consequences and noted that available evidence supports the need for such 
an effort.  
The potential importance of research on environmental chemicals and the microbiome is 
evident in the current scientific interest in the relationships between adverse health outcomes 
and perturbations in the microbiome. Before and since the National Academies (2018) report 
was published, workshops on the topic have brought diverse disciplines together to discuss 
the research that has begun (NAS, 2016; HESI, 2018); professional societies have hosted 
symposia (ISES, 2019; SOT, 2018); and journals in multiple disciplines continue to publish 
research, much of which was discussed in the National Academies report.  
The research strategies described in the National Academies (2018) report will, if 
implemented, clarify the importance to risk assessment and human health of understanding 
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2. THE MICROBIOME IN HUMANS AND ANIMAL MODELS 
The human body hosts great numbers of diverse microorganisms, as do all animals, 
including those used in research. The collection of microbes inhabiting a particular body site 
or niche is referred to as the microbiota, and significant variations in microbiota composition 
exist between and within organ systems. The most well-described microbiota are those 
representing body sites more readily sampled, such as the lower gastrointestinal tract, skin, 
and oral or nasal passages (HMP Consortium, 2012). Extensive efforts to characterize human 
microbiota have been spurred by interests in how host-associated microbes shape states of 
health or disease. Although current understanding of how microbiota specifically influence 
disease risk or disease heterogeneity is far from complete, the strength of associative 
evidence in many clinical contexts has motivated ongoing research to understand the 
microbial, metabolic, and pathophysiologic processes involved.   
In contrast to the term microbiota, the term microbiome is more thorough, referring to “all 
microorganisms on or in the body, their genes, and surrounding environmental conditions” 
(NASEM, 2018). The term is often used in conjunction with a specific body site, such as the 
gut, skin, or respiratory microbiome and captures the ecological contexts that shape microbial 
behaviors. For example, oxygen content, pH, and nutrient availability, among many other 
factors, all influence what microbes live where and explain the broad differences between the 
gut, skin and oral microbiomes. 
Notably, there is great variability between individuals in their microbiomes. This 
variability reflects a constellation of individual-specific factors, both endogenous (genetics, 
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exposures) (Markle et al., 2013; Trompette et al., 2014; Stein et al., 2016; Suez et al., 2014), 
and will be important to consider in attempts to understand how the microbiome influences 
health.  Moreover, there is growing recognition in murine model research that husbandry 
practices can greatly affect microbiota composition and potentially impact, even confound, 
measured effects of an intervention (Servick, 2016; Ericsson et al., 2018; Dickson et al., 
2018). It is important to note that in the vast majority of studies to date, the most commonly 
used technique to characterize microbiota (sequence analysis for the conserved bacterial 16S 
ribosomal RNA gene) does not provide direct readouts of microbial gene functions or 
products. As methods to characterize microbial functions improve, these new insights will 
advance understanding of the complex functional interactions occurring in microbiomes. This 
foundation is needed to inform the basis of microbiome variability between individuals, of 
the effects of microbiome perturbations resulting from exposures and other interventions, and 
to explain known associations between microbiome perturbation and disease states. 
A large body of evidence already exists showing that particular interventions or exposures 
can affect the assembly, maturation, and stability of human or mouse microbiomes. In one 
well-studied human context, exposures in early life—including home environment (e.g., 
proximity to domesticated animals), antibiotic use, and source of nutritional support 
(breastmilk versus infant formula)—can affect the gut microbiome and its trajectory of 
maturation in the first years of life (Li, Wang, & Donovan, 2014). This is an important 
developmental period for the immune system (Chung et al., 2012), and differences in the 
intestinal microbiome are linked to future risk of allergic diseases (Li et al., 2014). Similarly, 
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for childhood asthma (Teo et al., 2018). Among interventions, antibiotics most clearly and 
consistently alter microbiomes, most well-studied in the gut and in animal models (Morgun et 
al., 2015; Dethlefson & Relman, 2011). However, the short-term versus persistent effects of 
such can vary and differ by study design or clinical context.  Other studies that focus on the 
gut microbiome have shown that administration of non-antimicrobial agents (Wu et al., 2017; 
Suez et al., 2014) alter the intestinal microbiome. In some cases, mechanisms by which 
microbiota members process or transform a pharmacologic agent have been elucidated 
(Maurice, Haiser, & Turnbaugh, 2013; Spanogiannopoulos, Bess, Carmody, & Turnbaugh, 
2016). Clearly, these lines of evidence easily extend to consideration of other important 
scenarios that have yet to be studied. It is plausible that exposure to certain environmental 
chemicals could perturb human microbiomes, or conversely that chemicals could be 
processed and transformed by human microbiota, with downstream effects on risk for disease 
(NASEM, 2018).  
 
3. CHEMICAL AND MICROBIOME INTERACTIONS RELEVANT TO RISK 
ASSESSMENT 
Given this background, it is reasonable to postulate that the microbiome can play a role in 
the development of chemical toxicity. Two lines of evidence support such a role. First, as 
described above, it is well established that alterations in the microbiome can lead to adverse 
health outcomes. It is also reasonably well established that exposures to some chemicals can 
alter the microbiome. What remains to be established is whether various types of chemically 
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and apart from those induced through well-known toxicity mechanisms. Second, research has 
established that the chemical metabolism and uptake of at least some chemicals can be altered 
by the microbiome. Questions remain about the magnitude of the effect of the microbiome on 
the production of toxic metabolites and the role the microbiome may have in the kinetics of 
absorption, distribution, and elimination of chemicals (Diaz-Bone & Van de Wiele, 2010). 
It is not now possible to evaluate the significance of those possible pathways of 
microbiome-influenced toxicities. But there are good reasons to do the needed research. It is 
critically important to understand whether current methods for identifying chemical toxicities 
(hazards), dose-response relationships, and the most relevant measures of dose adequately 
reflect the influences of the microbiome. If they do not, and those influences are significant, 
then risk assessments based on data generated with the use of those methods will not provide 
adequate human risk characterizations (NASEM, 2018). 
The two principle sources of data for chemical risk assessments are observational 
epidemiology studies in selected human populations and studies in experimental animals 
(EPA, 2014). Investigations into the role of the microbiome in the production of observed 
toxicities have been rarely undertaken in either study type. Some might argue that, if the 
microbiome were somehow involved in the production of observed toxicities, its role would 
have been inherently captured in whatever outcomes were observed. Others might posit that 
determining whether and how the microbiome was involved, while of academic interest, is 
not essential for developing relevant and reliable risk assessments. This argument would have 
merit were it not for the variability of the microbiome. For that reason, observations of 
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population) might have little or no relevance to other populations (e.g., children, the aged, 
people with chronic diseases) that have substantially different microbiome features and 
functions. The extent to which observations lack relevance and the direction of the difference 
(i.e., are unstudied populations more or less susceptible or might they experience completely 
different types of toxicity?) cannot be ascertained without investigation of the role played by 
the microbiome and the specific characteristics of microbiome functions that were involved. 
Most of the toxicity data used in risk assessment are developed in studies in animal 
models, and the compositional and functional differences in microbiomes between animals 
and humans have not been well studied (HMP Consortium, 2012). Observations of 
microbiome-mediated toxicities in standard animal models are, therefore, of uncertain 
relevance to humans. 
In addition to questions of microbiome-mediated toxicities or hazards, there are major 
unknowns about dose-response relationships and relevant measures of dose, both essential for 
risk characterization (Dietert & Silbergeld, 2015). At present, scientists do not know how the 
microbiome is altered as chemical dose changes, and they do not know how the dose-
response relationship of microbiome perturbations is related to the dose-relationship of the 
ultimate manifestation of toxicity.  That knowledge will be necessary to determine “effect” 
and “no effect” doses for risk assessment. The added problem of identifying the measure of 
dose most relevant to the microbiome perturbation of interest will be difficult to solve. Is it, 
for example, only the dose that reaches the relevant site of microbiome perturbation and, if 
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Until there is better understanding of whether, and through what mechanisms, the 
microbiome influences chemical toxicity, and until there are relevant data on dose-response 
relationships and measures of dose specific to the toxic effects, risk assessments cannot with 
any confidence reflect influences of the microbiome and might mischaracterize human risks 
to unknown degrees. 
Published research in chemical-microbiome interactions suggest that data are being 
developed that even now could help characterize the influence of the microbiome and, in the 
future, will be important to incorporate into risk assessments.  
 
4. USING EMERGING DATA IN RISK ASSESSMENTS 
Data on microbiome-chemical interactions that better define pharmacokinetics of exposure 
for a few chemicals might already be available for use in risk assessments. When the action of the 
microbiome on a chemical before absorption into cells can be quantified, the amount of 
bioavailable chemical can be better estimated, and previous exposure estimates might be increased 
or decreased accordingly. In addition, current research indicates that data will become available 
on the chemical metabolites produced by microbiomes. Laboratory animal data on the metals 
mercury and arsenic suggest that exposure estimates could shift to new parent and metabolite 
ratios and that toxicity evaluations could shift to different chemical metabolites (Van de Wiele et 
al., 2010; Diaz-Bone & Van de Wiele 2010). However, research is needed to characterize and 
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based pharmacokinetic models that incorporate the role of the microbiome could contribute to 
improved understanding of dose response and the relevance of animal studies to humans. 
Risk assessors will find it more difficult to characterize and use emerging data on chemical-
induced change or harm to the microbiome as a health effect. Comprehensive data on how 
changes to the microbiome alter host health are not currently available. In addition, current 
studies are not designed to separate a chemical’s direct effect on the host from the chemical’s 
effect on the microbiome, although the concept has been tested by examining the effect of a 
chemically altered microbiome transplanted in a new host (Suez et al., 2014). A chemical that 
alters the community composition and function of a microbiome might lead to a direct health 
effect, but also might alter chemical exposures by damaging the metabolic capacity of the 
microbiome or changing the environment that supports microbiome-induced chemical 
metabolism. For example, the gut microbiome has a regulatory effect on the host liver’s 
production of bile acids (Wahlstrom, Kovatcheva-Datchary, Stahlman, Khan, Backhed, & 
Marschall, 2017). Research is needed to examine the potential that change in the microbiome 
might result in a change in the gut environment that could both alter optimal function and alter 
the microbiome’s effect on the chemical. To use emerging data on a chemical’s effect on the 
microbiome, the role of the microbiome in supporting a healthy organism needs to be well 
characterized and adverse human health effects (in the absence of chemical exposure) from an 
impaired microbiome need to be defined for both function and composition. Indeed, the very 
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One of the most exciting possibilities in chemical-microbiome research is the potential for 
new interpretations of variation in responses to chemicals between and within species. A wide 
range of environmental, developmental, and physiological determinants of microbiome variation 
might be responsible for between-study differences in exposure, health effects, and dose-response. 
A new risk assessment activity will likely involve relating emerging data on pharmaco-kinetics 
and health consequences of chemical-microbiome relationships to an understanding of variation 
of animal and human microbiomes. A new field of inquiry for risk assessors who work with any 
specific risk assessment and target population will be to evaluate the extent to which 
epidemiology and toxicity studies, particularly standardized studies used repeatedly in the past for 
regulatory purposes, sufficiently evaluate the similarity of microbiomes of studied populations to 
the target population (e.g., the US general population that includes infants). A key question for 
risk assessors is which populations (e.g., infants with limited diversity in microbiomes, persons 
with compromised microbiomes from illness) are more or less susceptible to the adverse effects of 
chemical-microbiome interactions. 
The same environmental factors that contribute to chemical exposure might also alter 
microbiome composition and function (e.g., quality of ambient air, water, and soil; household and 
workplace environments; an individual’s diet; use of personal care products; nutrition; and use of 
health supplements and pharmaceuticals). Risk assessors need to be aware that while a chemical 
might not be present in a particular medium, product, or location, microbiomes shaped by 
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Environmental chemical risk assessors typically have only data from toxicity studies 
conducted using highly controlled exposure conditions and well-defined laboratory animals. 
Historically, such studies do not describe the composition and function of the microbiome in the 
animals. However, comparing results of existing studies (such as studies of gut or lung health) 
across species or exposure paradigms might suggest differences in microbiome-related factors. 
Environmental epidemiology studies often produce disparate or conflicting results, which prevent 
them from being used in risk assessment. Understanding the microbiome variability in the 
observed human populations might help to explain the study differences and allow greater weight 
to be applied to epidemiology data or allow risk assessors to select among studies those that are 
most relevant based on knowledge of chemical-microbiome interactions. 
 
5.  CHALLENGES AND OPPORTUNITIES FOR RISK ASSESSORS 
Risk assessors can have a role today in guiding chemical-microbiome research to focus on 
environmentally relevant exposures, dose-response relationships, and salient health effects. As in 
much nascent exposure, toxicity, and epidemiology research, high levels of chemical exposure or 
microbiome disruption might be used to demonstrate chemical-microbiome interactions. How the 
effects from high exposures scale to environmentally relevant exposures will need to be explored, 
especially as high-throughput research is conducted. Similarly, risk assessors will need to grapple 
with defining what is adverse for microbiome disruption and will need to pay attention to 
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may be identified through -omics research) that might lead to microbiome disruption. Risk 
assessors must be involved in reaching agreement on composition and functional measures of 
microbiome disruption that will be considered an adverse health effect. In addition, measurement 
parameters and interpretation need to be agreed upon for such concepts as redundancy and 
conservation of function, functional recovery of the microbiome, local versus distal effects, and 
acute versus long-term effects. 
Risk assessors should advocate for measures of microbiome composition and function in 
current exposure, toxicity, and epidemiology studies. They should also advocate for developing 
and implementing high-throughput testing that could implicate or rule out microbiome-chemical 
interactions. As high-throughput data are developed, it is likely that risk assessors will need to 
advocate for additional data on the nature and magnitude of the chemical-microbiome interaction 
to extrapolate study results to target populations. Additionally, they will be able to identify 
candidate chemicals for further testing based on what is now understood about the role of the 
microbiome. As described in the National Academies (2018) report, risk assessors, for example, 
might want testing to include chemicals for which large intraspecies variability has been found in 
epidemiology or toxicity studies, or chemicals with health end points that have been linked to 
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Important discoveries are anticipated from this nascent field that could profoundly affect 
risk assessment.  Risk assessors and manager should monitor new findings but should also be 
involved in the research so that the research will yield useful information for risk assessment.  
As described above, risk assessors can contribute to identifying chemicals of interest and 
can identify those species and strains of laboratory animals whose microbiomes might be 
most important to characterize and contrast with humans. In addition, risk assessors have 
experience in understanding the challenges of defining adverse effects and can help 
determine how to quantitate harm from changes in microbiomes. They can also help to 
interpret quantitative data on chemical-microbiome interactions to improve dose-response 
estimates. Finally, risk assessors can begin today to educate risk managers in the importance 
of microbiome research for improving risk assessments. 
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